KR950016759A - Antibiotic Anticancer Composition - Google Patents
Antibiotic Anticancer Composition Download PDFInfo
- Publication number
- KR950016759A KR950016759A KR1019930032093A KR930032093A KR950016759A KR 950016759 A KR950016759 A KR 950016759A KR 1019930032093 A KR1019930032093 A KR 1019930032093A KR 930032093 A KR930032093 A KR 930032093A KR 950016759 A KR950016759 A KR 950016759A
- Authority
- KR
- South Korea
- Prior art keywords
- anticancer
- present
- anthracycline
- anticancer agent
- composition
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 심장독성이 경감된 항암항생 조성물을 제공하며, 이 조성물은 유효성분으로서 안스라사이클린계 항암제와 안스라사이클린계 항암제 대하여 당량비로 0.01∼30배의 아데노신(Adenosine)을 함유함을 특징으로 한다. 본 발명의 조성물에 사용되는 안스라사이클린계 항생항암제는 독소루비신, 에퍼두비신, 다우노루비신, 피라루비신 또는 이다루비신이다.The present invention provides an anticancer antibiotic composition with reduced cardiotoxicity, and the composition contains 0.01 to 30 times of adenosine (Adenosine) in an equivalent ratio with respect to the anthracycline anticancer agent and the anthracycline anticancer agent as an active ingredient. do. The anthracycline antibiotic agent used in the composition of the present invention is doxorubicin, efferduvicin, daunorubicin, pyrarubicin or idarubicin.
본 발명의 항생항암 조성물은 그에 포함되어 있는 아데노신이 안스라사이클린제 항암제가 갖는 심장독성을 경감시키는 작용을 하며, 따라서 본 발명의 조성물은 심장독성이 경감되어 있기 때문에 종래보다 안스라사이플린게 항암제의 투여량을 높이므로써 중강된 항암작용을 발휘할 수 있다.The anticancer anticancer composition of the present invention acts to reduce the cardiotoxicity of the adenosine contained in the anticancer agent of anthracycline. Therefore, the anticancer anticancer agent of the present invention is more effective than the conventional anticancer agent because the antitoxicity of the anticancer agent of the present invention is alleviated. Increasing the dose of can exert a moderate anticancer action.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019930032093A KR950016759A (en) | 1993-12-31 | 1993-12-31 | Antibiotic Anticancer Composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019930032093A KR950016759A (en) | 1993-12-31 | 1993-12-31 | Antibiotic Anticancer Composition |
Publications (1)
Publication Number | Publication Date |
---|---|
KR950016759A true KR950016759A (en) | 1995-07-20 |
Family
ID=66853377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019930032093A KR950016759A (en) | 1993-12-31 | 1993-12-31 | Antibiotic Anticancer Composition |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR950016759A (en) |
-
1993
- 1993-12-31 KR KR1019930032093A patent/KR950016759A/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU591309B2 (en) | Taxol derivatives, their preparation and pharmaceutical compositions containing them | |
BR9712304A (en) | Use of pyrazole-1-benzyl-3- (substituted hetaryl) derivatives-melts | |
NZ336344A (en) | Endoparasiticidal and ectoparasiticidal compositions comprising an avermectin, ivermectin or milemycin with antagonists or agonists of nicotinergic acetylcholine receptors | |
ES2123323T3 (en) | ASSOCIATION OF A COMPOUND WITH ANTIMICROBIAL ACTIVITY (FOR EXAMPLE LIPOAMINOACIDO N, N-OCTANOILGLICINA) AND OF A GLYCEROL MONO-ALKYLETER AND ITS USE AS ANTIMICROBIAL AGENT. | |
KR910004185A (en) | Compounds and their use for reversing multidrug resistance of cancer cells against cytotoxin agents | |
EP0375367A3 (en) | Biocidal compositions | |
EP0077377A4 (en) | Anthracycline glycoside compositions, their use and preparation. | |
BR9810985A (en) | Topical application of a combination of benzoyl peroxide and a second active ingredient | |
IE852593L (en) | Compositions containing anthracycline glycosides | |
BR0008453A (en) | Synergistically anti-tumor composition | |
BR9200786A (en) | USE OF HYDROPHYL PENETRATION AGENTS AND DERMATOLOGICAL COMPOSITION FOR THE TREATMENT OF ONICOMYCOSIS | |
BR1100612A (en) | Suitable saccharide consisting of two saccharides and one spacer, their use and pharmaceutical composition | |
ATE173738T1 (en) | ALKYLTHIOALKYLAVERMECTINES ARE ACTIVE ANTIPARASITE ACTIVES | |
BG102250A (en) | The use of marigold-extracted glycosides for the treatment of psoriasis | |
MX9300576A (en) | IMPROVEMENTS IN GAME MATERIAL. | |
KR920007627A (en) | Anticorrosive composition | |
KR950007857A (en) | Rapamycin preparations for oral administration | |
Du et al. | Glycosidic constituents from in vitro Anoectochilus formosanus | |
ES2133380T3 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING ANTHRACICLINE GLYCOSIDES LINKED TO POLYMER DERIVATIVES, AND THEIR PREPARATION PROCEDURE. | |
KR950016759A (en) | Antibiotic Anticancer Composition | |
KR910005876A (en) | Minimal pharmaceutical compositions for the treatment of capillary weakness | |
KR890000009A (en) | Agricultural bioactive agents | |
GB2002754A (en) | Antitumor anthracycline antibiotics | |
FR2705094B1 (en) | New lupane derivatives, their preparation and the pharmaceutical compositions containing them. | |
KR970064618A (en) | TNFα activity inducing composition containing ginsenoside |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |